Impact of allergic rhinitis and specific subcutaneous immunotherapy on peripheral blood basophils of patients sensitized to Dermatophagoides pteronyssinus

Allergy, Asthma & Clinical Immunology

Ana Lopes⁴  Patrícia Azenha³  Cristina Teodósio¹  Maria Inácio⁴  Isabel Silva⁴  Graça Loureiro²  António Martinho⁴  António S Luís²  Hélder Trindade⁴  Celso Pereira²  Artur Paiva³ 

[1] General Cytometry Service, Cancer Research Center (IBMCC-CSIC/USAL and IBSAL) and Department of Medicine, University of Salamanca, Salamanca, Spain

[2] Immunoallergology Department, University Hospital of Coimbra, 3000-075, Coimbra, Portugal

[3] College of Health Technology of Coimbra, São Martinho do Bispo, 3046-854, Coimbra, Portugal

[4] Blood and Transplantation Center of Coimbra, Portuguese Institute of Blood and Transplantation, Edifício São Jerónimo, 4 Piso, Praceta Mota Pinto, 3001-301, Coimbra, Portugal

关键词: Specific subcutaneous immunotherapy;    Tryptase;    Histamine N-methyltransferase;    Basophils;    Dermatophagoides pteronyssinus;    Allergic rhinitis;   

Others  :  792120
DOI  :  10.1186/1710-1492-9-40

 received in 2013-06-27, accepted in 2013-09-28,  发布年份 2013

【 摘 要 】

Background

Basophils are important effectors cells in allergic rhinitis (AR) since they are involved in immunoglobulin (Ig) E – mediated inflammation and in the release of pro-inflammatory mediators. Specific subcutaneous immunotherapy (SCIT) provides clear immunologic modulation in some immune cells, however its systemic effects on basophils are not well known.

Methods

Peripheral blood (PB) samples from 43 patients with allergic rhinitis mono-sensitized to Dermatophagoides pteronyssinus (Dpt) [33 of them under SCIT with allergoid Dpt extract, in maintenance dose (SCIT), with evaluation just before SCIT injection (SCIT-T0) and 4 hours later (SCIT-T4) and the other 10 Dpt allergic patients never having, in the past, undergone specific immunotherapy treatment (NSIT)], and 15 healthy age- and gender-matched controls (HG), were analyzed. For each sample, the total (t-IgE) and specific IgE (s-IgE) was performed, as well as, the relative frequency and absolute number of PB basophils and receptor-bound IgE and IgG expression were evaluated by flow cytometry and the Histamine N-methyltransferase (HNMT) and tryptase α/β1 (TPSAB1) gene expression was assessed by real-time PCR.

Results

Higher levels of receptor-bound IgE were observed in SCIT patients, which are correlated with the levels of serum t-IgE and s-IgE, whereas no significant differences were observed for receptor-bound IgG. Regarding HNMT mRNA expression, significantly lower expression levels were detected in AR patients compared to HG, independently of type of therapy. Moreover a negative correlation was found between HNMT gene expression and time under SCIT. Conversely, tryptase gene expression was significantly up-regulated in NSIT when compared to HG; however in SCIT patients, tryptase gene expression was significantly decreased than in NSIT patients. No differences were found for any parameter between SCIT-T0 and SCIT-T4 with exception of a transient increased expression of tryptase in SCIT-T4.

Conclusion

PB basophils from patients with AR show altered functional features, which seems to be influenced by SCIT, suggesting that these cells could be useful to clarify the SCIT triggered mechanisms at a systemic level.

【 授权许可】

   
2013 Lopes et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Dykewicz MS, Hamilos DL: Rhinitis and sinusitis. J Allergy Clin Immunol 2010, 125:S103-S115.
• [2]Sin B, Togias A: Pathophysiology of allergic and nonallergic rhinitis. Proc Am Thorac Soc 2011, 8:106-114.
• [3]Montoro J, Sastre J, Jauregui I, Bartra J, Davila I, Del Cuvillo A, Ferrer M, Mullol J, Valero A: Allergic rhinitis: continuous or on demand antihistamine therapy? J Investig Allergol Clin Immunol 2007, 17(Suppl 2):21-27.
• [4]Broide DH: Allergic rhinitis: Pathophysiology. Allergy Asthma Proc 2010, 31:370-374.
• [5]Skoner DP: Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001, 108:S2-S8.
• [6]Rondon C, Campo P, Togias A, Fokkens WJ, Durham SR, Powe DG, Mullol J, Blanca M: Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol 2012, 129:1460-1467.
• [7]Galli SJ, Tsai M, Piliponsky AM: The development of allergic inflammation. Nature 2008, 454:445-454.
• [8]Pawankar R, Mori S, Ozu C, Kimura S: Overview on the pathomechanisms of allergic rhinitis. Asia Pac allergy 2011, 1:157-167.
• [9]Shiraishi Y, Jia Y, Domenico J, Joetham A, Karasuyama H, Takeda K, Gelfand EW: Sequential engagement of FcepsilonRI on Mast Cells and Basophil Histamine H(4) Receptor and FcepsilonRI in Allergic Rhinitis. J Immunol 2013, 190:539-548.
• [10]Min B: Basophils: what they 'can do’ versus what they 'actually do’. Nature immunology 2008, 9:1333-1339.
• [11]Bochner BS: Systemic activation of basophils and eosinophils: markers and consequences. J Allergy Clin Immunol 2000, 106:S292-S302.
• [12]Suzukawa M, Hirai K, Iikura M, Nagase H, Komiya A, Yoshimura-Uchiyama C, Yamada H, Ra C, Ohta K, Yamamoto K, Yamaguchi M: IgE- and FcepsilonRI-mediated migration of human basophils. Int Immunol 2005, 17:1249-1255.
• [13]Sanz ML, Sanchez G, Gamboa PM, Vila L, Uasuf C, Chazot M, Dieguez I, De Weck AL: Allergen-induced basophil activation: CD63 cell expression detected by flow cytometry in patients allergic to Dermatophagoides pteronyssinus and Lolium perenne. Clin Exp Allergy 2001, 31:1007-1013.
• [14]Lund G, Jacobi H, Skov PS, Holm J, Lund K: Effect on cell surface markers following allergen-induced desensitization of human whole-blood basophils. Int Arch Allergy Immunol 2010, 153:323-334.
• [15]Prussin C, Metcalfe DD: 5. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2006, 117:S450-S456.
• [16]Packard KA, Khan MM: Effects of histamine on Th1/Th2 cytokine balance. Int Immunopharmacol 2003, 3:909-920.
• [17]Ogasawara M, Yamauchi K, Satoh Y, Yamaji R, Inui K, Jonker JW, Schinkel AH, Maeyama K: Recent advances in molecular pharmacology of the histamine systems: organic cation transporters as a histamine transporter and histamine metabolism. J Pharmacol Sci 2006, 101:24-30.
• [18]Dy M, Schneider E: Histamine-cytokine connection in immunity and hematopoiesis. Cytokine Growth Factor Rev 2004, 15:393-410.
• [19]Bahceciler NN, Galip N: Comparing subcutaneous and sublingual immunotherapy: what do we know? Curr Opin Allergy Clin Immunol 2012, 12:640-647.
• [20]Cappella A, Durham SR: Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin immunotherapeutics 2012, 8:1499-1512.
• [21]Moote W, Kim H: Allergen-specific immunotherapy. Allergy Asthma Immunol 2011, 7 Suppl 1:S5.
• [22]Jutel M, Akdis CA: Immunological mechanisms of allergen-specific immunotherapy. Allergy 2011, 66:725-732.
• [23]Shim JY, Kim BS, Cho SH, Min KU, Hong SJ: Allergen-specific conventional immunotherapy decreases immunoglobulin E-mediated basophil histamine releasability. Clin Exp Allergy 2003, 33:52-57.
• [24]Cady CT, Powell MS, Harbeck RJ, Giclas PC, Murphy JR, Katial RK, Weber RW, Hogarth PM, Johnson S, Bonvini E, et al.: IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB. Immunology letters 2010, 130:57-65.
• [25]Bousquet J, Schunemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, Bonini S, Boulet LP, Bousquet PJ, Brozek JL, et al.: Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 2012, 130:1049-1062.
• [26]Bousquet J: Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 2000, 30(Suppl 1):2-5.
• [27]Pereira C, Loureiro G, Martinho A, Paiva A, Tavares B, Machado D, Nunes R, Pedreira S, Henriques A, Pais ML, Segorbe-Luis A: T cell receptor excision circles (TREC) and recent thymic migrant cells in specific immunotherapy and respiratory allergy to Dermatophagoides pteronyssinus. Eur Ann Allergy Clin Immunol 2012, 44:61-72.
• [28]Han X, Jorgensen JL, Brahmandam A, Schlette E, Huh YO, Shi Y, Awagu S, Chen W: Immunophenotypic study of basophils by multiparameter flow cytometry. Arch Pathol Lab Med 2008, 132:813-819.
• [29]Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome biology 2002, 3:RESEARCH0034.
• [30]Calderon MA, Demoly P, Gerth Van Wijk R, Bousquet J, Sheikh A, Frew A, Scadding G, Bachert C, Malling HJ, Valenta R, et al.: EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Sci allergy 2012, 2:20. BioMed Central Full Text
• [31]Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA: IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003, 33:1205-1214.
• [32]Uermosi C, Beerli RR, Bauer M, Manolova V, Dietmeier K, Buser RB, Kundig TM, Saudan P, Bachmann MF: Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol 2010, 126:375-383.
• [33]Akdis M, Akdis CA: Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007, 119:780-791.
• [34]Klimek L, Wolf H, Mewes T, Dormann D, Reske-Kunz A, Schnitker J, Mann W: The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol 1999, 103:47-53.
• [35]Nullens S, Sabato V, Faber M, Leysen J, Bridts CH, De Clerck LS, Falcone FH, Maurer M, Ebo DG: Basophilic histamine content and release during venom immunotherapy: insights by flow cytometry. Cytometry Part B, Clinical cytometry 2013, 84:173-178.
• [36]Gauvreau GM, Lee JM, Watson RM, Irani AM, Schwartz LB, O’Byrne PM: Increased numbers of both airway basophils and mast cells in sputum after allergen inhalation challenge of atopic asthmatics. Am J Respir Crit Care Med 2000, 161:1473-1478.
• [37]Falcone FH, Haas H, Gibbs BF: The human basophil: a new appreciation of its role in immune responses. Blood 2000, 96:4028-4038.
• [38]Denburg JA, Van Eeden SF: Bone marrow progenitors in inflammation and repair: new vistas in respiratory biology and pathophysiology. Eur Respir J 2006, 27:441-445.
• [39]Stone KD, Prussin C, Metcalfe DD: IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2010, 125:S73-S80.
• [40]Kawakami T, Galli SJ: Regulation of mast-cell and basophil function and survival by IgE. Nature reviews Immunology 2002, 2:773-786.
• [41]Kubo S, Matsuoka K, Taya C, Kitamura F, Takai T, Yonekawa H, Karasuyama H: Drastic up-regulation of Fcepsilonri on mast cells is induced by IgE binding through stabilization and accumulation of Fcepsilonri on the cell surface. J Immunol 2001, 167:3427-3434.
• [42]Pevec B, Radulovic Pevec M, Stipic Markovic A, Batista I, Rijavec M, Silar M, Kosnik M, Korosec P: House dust mite-specific immunotherapy alters the basal expression of T regulatory and FcepsilonRI pathway genes. Int Arch Allergy Immunol 2012, 159:287-296.
• [43]Rajakulasingam K, Durham SR, O’Brien F, Humbert M, Barata LT, Reece L, Kay AB, Grant JA: Enhanced expression of high-affinity IgE receptor (Fc epsilon RI) alpha chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells. J Allergy Clin Immunol 1997, 100:78-86.
• [44]Di Lorenzo G, Mansueto P, Pacor ML, Rizzo M, Castello F, Martinelli N, Ditta V, Lo Bianco C, Leto-Barone MS, D’Alcamo A, et al.: Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol 2009, 123:1103-1110. 1110 e1101-1104
• [45]Jayasekera NP, Toma TP, Williams A, Rajakulasingam K: Mechanisms of immunotherapy in allergic rhinitis. Biomed Pharmacother 2007, 61:29-33.
• [46]Hirata N, Takeuchi K, Ukai K, Sakakura Y: Expression of histidine decarboxylase messenger RNA and histamine N-methyltransferase messenger RNA in nasal allergy. Clin Exp Allergy 1999, 29:76-83.
• [47]Jutel M, Muller UR, Fricker M, Rihs S, Pichler WJ, Dahinden C: Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin Exp Allergy 1996, 26:1112-1118.
• [48]Jutel M, Blaser K, Akdis CA: Histamine receptors in immune regulation and allergen-specific immunotherapy. Immunol Allergy Clin North Am 2006, 26:245-259. vii
• [49]Novak N, Mete N, Bussmann C, Maintz L, Bieber T, Akdis M, Zumkehr J, Jutel M, Akdis C: Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2. J Allergy Clin Immunol 2012, 130:1153-1158. e1152
• [50]Pichler CE, Helbling A, Pichler WJ: Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 2001, 56:301-306.
• [51]Siegmund R, Vogelsang H, Machnik A, Herrmann D: Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy. J Allergy Clin Immunol 2000, 106:1190-1195.
• [52]Krishna MT, Huissoon AP: Clinical immunology review series: an approach to desensitization. Clin Exp Immunol 2011, 163:131-146.
• [53]Larson D, Hubner MP, Torrero MN, Morris CP, Brankin A, Swierczewski BE, Davies SJ, Vonakis BM, Mitre E: Chronic helminth infection reduces basophil responsiveness in an IL-10-dependent manner. J Immunol 2012, 188:4188-4199.